Last reviewed · How we verify
Public Health Service of Amsterdam — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
1 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Fosfomycin Oral Suspension | Fosfomycin Oral Suspension | marketed | Cell wall synthesis inhibitor | MurA (enolpyruvate transferase) | Infectious Disease | |
| Gentamicin Sulfate, Injectable | Gentamicin Sulfate, Injectable | phase 3 | Aminoglycoside antibiotic | Bacterial 30S ribosomal subunit | Infectious Disease |
Therapeutic area mix
- Infectious Disease · 2
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Assistance Publique Hopitaux De Marseille · 1 shared drug class
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla · 1 shared drug class
- Hospital General Universitario Elche · 1 shared drug class
- Murdoch Childrens Research Institute · 1 shared drug class
- Mylan Inc. · 1 shared drug class
- Oslo University Hospital · 1 shared drug class
- Seattle Children's Hospital · 1 shared drug class
- Shanghai Pulmonary Hospital, Shanghai, China · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Public Health Service of Amsterdam:
- Public Health Service of Amsterdam pipeline updates — RSS
- Public Health Service of Amsterdam pipeline updates — Atom
- Public Health Service of Amsterdam pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Public Health Service of Amsterdam — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/public-health-service-of-amsterdam. Accessed 2026-05-18.